Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma

被引:0
|
作者
Bojie Dai
X. Frank Zhao
Krystyna Mazan-Mamczarz
Patrick Hagner
Sharon Corl
El Mustapha Bahassi
Song Lu
Peter J. Stambrook
Paul Shapiro
Ronald B. Gartenhaus
机构
[1] University of Maryland,Department of Medicine
[2] Marlene & Stewart Greenebaum Cancer Center,Department of Pathology
[3] University of Maryland School of Medicine,Department of Molecular Genetics
[4] University of Cincinnati,Department of Pharmaceutical Sciences
[5] University of Maryland School of Pharmacy,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Distinct oncogenic signalling cascades have been associated with non-Hodgkin lymphoma. ERK1/2 signalling elicits both transcriptional and post-transcriptional effects through phosphorylation of numerous substrates. Here we report a novel molecular relationship between ERK1/2 and CHK2, a protein kinase that is a key mediator of the DNA damage checkpoint that responds to DNA double-strand breaks. Our studies are the first to demonstrate the co-localization and overexpression of ERK1/2 and CHK2 in diffuse large B-cell lymphoma (DLBCL). The physical interaction between ERK and CHK2 was highly dependent on phosphorylated Thr 68 of CHK2. Concurrent administration of an ERK inhibitor enhances the antitumour activity of CHK2 inhibition in both a human DLBCL xenograft model as well as primary human DLBCL cells. Our data suggest a functional interaction between ERK and CHK2 and support the potential combined therapeutic targeting of ERK and CHK2 in human DLBCL.
引用
收藏
相关论文
共 50 条
  • [1] Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma
    Dai, Bojie
    Zhao, X. Frank
    Mazan-Mamczarz, Krystyna
    Hagner, Patrick
    Corl, Sharon
    Bahassi, El Mustapha
    Lu, Song
    Stambrook, Peter J.
    Shapiro, Paul
    Gartenhaus, Ronald B.
    NATURE COMMUNICATIONS, 2011, 2
  • [2] Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma
    Gascoyne, RD
    HEMATOLOGY JOURNAL, 2004, 5 : S144 - S148
  • [3] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
    Ci, Weimin
    Polo, Jose M.
    Melnick, Ari
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (04) : 381 - 390
  • [4] Unclassifiable B-cell lymphoma: Between diffuse large B-cell lymphoma and Burkitt lymphoma
    Mandi, Y.
    Malihy, A.
    Kettani, F.
    Alaammari, I.
    Khmou, M.
    Touri, S.
    Rouas, L.
    Lamalmi, N.
    El Khorassani, M.
    Alhamany, Z.
    ARCHIVES DE PEDIATRIE, 2015, 22 (06): : 661 - 664
  • [5] The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma
    Derenzini, Enrico
    Iacobucci, Ilaria
    Brighenti, Elisa
    Cattina, Federica
    Casadei, Beatrice
    Davis, Richard Eric
    Pileri, Stefano
    Martinelli, Giovanni
    Baccarani, Michele
    Zinzani, Pier Luigi
    CANCER RESEARCH, 2012, 72
  • [6] Molecular pathogenesis of diffuse large B-cell lymphoma
    Schneider, Christof
    Pasqualucci, Laura
    Dalla-Favera, Riccardo
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2011, 28 (02) : 167 - 177
  • [7] Molecular Classification of Diffuse Large B-Cell Lymphoma
    Baa, Annie Kanchan
    Rasheed, Azgar Abdul
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (04) : 356 - 359
  • [8] Molecular pathogenesis of diffuse large B-cell lymphoma
    Lossos, IS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) : 6351 - 6357
  • [9] The molecular biology of diffuse large B-cell lymphoma
    Frick, Mareike
    Doerken, Bernd
    Lenz, Georg
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (06) : 369 - 379
  • [10] Molecular Dissection of Diffuse Large B-Cell Lymphoma
    Pasqualucci, Laura
    BLOOD, 2014, 124 (21)